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Polo-Like Kinase 1 Mediated Regulation of Androgen Receptor: Potential Role in the Development of 
Castration-resistant Prostate Cancer
Xavier Moore, Lilia Gheghiani, Ph.D., & Zheng Fu, Ph.D.
• Prostate cancer (PCa) is among the most common cancers and is the second highest cause of cancer-related 
deaths in American men. 
• The androgen receptor (AR) is a nuclear receptor transcription factor, activated by dihydrotestosterone (DHT), 
that is required for normal prostate development and homeostasis.
• AR is subject to multiple post-translational modifications, including phosphorylation, that regulate protein 
stability, localization, and activity.
• Initially, PCa requires AR signaling for growth providing the clinical basis for androgen deprivation therapy 
(ADT), however, most patients relapse to castration-resistant prostate cancer (CRPC).
• Relapses have been attributed to receptor overexpression, intratumoral androgen biosynthesis, and aberrant 
regulation of AR-mediated signaling pathways.
• Polo-like kinase 1 (PLK1) is a serine/threonine kinase that is overexpressed in PCa and overexpression levels 
are positively correlated with cancer aggressiveness and poorer clinical outcome. 
• PLK1 upregulation causes oncogenic transformation, epithelial-to-mesenchymal transition, and increased 
motility in prostate epithelial cells; and inhibition causes mitotic arrest and apoptosis. 
• Gene expression profiling comparing androgen-independent and androgen-dependent prostate cancers shows 
an upregulation of PLK1 in androgen-independent cancers.
• PLK1 inhibitors in combination with androgen signaling inhibitors (ASI) enabled ASI resistance to be 
overcome in patient-derived tumor xenografts.
• In overexpression conditions, AR and PLK1 form a complex that can be immunoprecipitated (data not 
published).
• These data suggest a potential role of PLK1 in the transition to CRPC.
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• The data presented herein provides preliminary evidence to support an endogenous interaction that results in 
phosphorylation of AR by PLK1.
• A number of additional experiments must be conducted to strengthen these findings, these include reciprocal co-
IPs, in vitro kinase assays with phosphomutant substrate, and in vivo phosphorylation experiments.
• Following these conformational studies, we will investigate the functional significance of this interaction. 
However, we hypothesize that phosphorylation of AR results in nuclear translocation and increased transcription 
factor activity, likely in a ligand-independent manner. 
• Characterization of this interaction could elucidate a molecular driving force behind CRPC development 
potentially offering a novel therapeutic avenue for those suffering from this lethal disease.
PLK1 and AR interact endogenously:
PLK1 phosphorylates AR in vitro:
Results
Results
Figure 1. Mitotically arrested C4-2B cells were subjected 
to co-immunoprecipitation using anti-PLK1 antibodies. 
Immunoblotting was carried out using anti-AR and anti-
PLK1 antibodies.
Figure 2. AR is phosphorylated by PLK1. (A) An in vitro kinase 
assay was performed using commercially obtained His-tagged 
PLK1 as the kinase and GST-tagged full-length AR purified 
from bacteria as substrate. For immunoblotting, the membrane 
was probed with phospho-serine and phospho-threonine 
antibodies. An anti-GST antibody was used as a loading control. 
(B) An in vitro kinase assay was performed with GST-tagged N-
terminal AR as substrate. (C) GST-tagged C-terminal AR was 
used as substrate in an in vitro kinase assay.
• Current treatment options for CRPC are limited; androgen biosynthesis inhibitor abiraterone (Zytiga) and AR 
antagonist enzalutamide (Xtandi) offer more time for patients, but the prognosis remains terminal. 
• Gaps in our understanding of the molecular changes associated with CRPC development hinder the 
development of mechanism-based therapies for use in this advanced disease stage. 
• This project sought to investigate the role of PLK1 in the development of CRPC
• We hypothesized an endogenous interaction between PLK1 and AR resulting in a PLK1-mediated 
phosphorylation of AR
• We sought to investigate if an endogenous interaction 
between PLK1 and AR could be detected 
• For this experiment, C4-2B cells were used as they are 
an androgen-independent cell line derived from the 
bone metastases of castrated nude mice implanted with 
LNCaP xenographs.  
• Cells were arrested in mitosis to investigate the cell 
cycle dependency after being unable to obtain signal in 
asynchronous cells. 
• Mitotically arrested C4-2B cells were lysed and 
subjected to co-immunoprecipitation, revealing that 
PLK1 and AR form an endogenous complex (Fig. 1). 
• Due to PLK1 consensus sequences being present 
in the AR primary structure, we hypothesized that 
AR may be a phosphorylation substrate of PLK1. 
• Full length AR was incubated with the kinase 
followed by immunoblotting with anti-phospho-
serine and anti-phospho-threonine antibodies, 
which revealed strong phosphorylation at serine 
and threonine residues (Fig. 2A). 
• The AR N-terminal domain (amino acids 1-504) 
produced a strong serine phosphorylation band and 
a faint threonine band (Fig. 2B). 
• The reverse was observed for the C-terminal 
domain (amino acids 505-519), in which strong 
phosphorylation was observed for threonine but 
not serine (Fig. 2C). 
• An anti-GST antibody was used as a loading 
control and revealed mobility shifts were observed 
for the full length and c-terminal (Figs. 2A and C). 
• Collectively, these data suggest that AR is a 
phosphorylation substrate of PLK1.
Introduction
Significance and Objectives
Summary and Future Directions
Acknowledgements
